Table 2.
Univariate analysis.
| HAPLOD (n = 29) | MSD (n = 20) | URD (n = 19) | p value | |
|---|---|---|---|---|
| % 95CI | % 95CI | % 95CI | ||
| Acute GVHD | ||||
| Grade 2–4 | 24% (13–46) | 35% (19–64) | 58% (39–85) | 0.024 |
| Grade 3–4 | 3% (1–24) | 15% (5–43) | 16% (6–45) | 0.169 |
| Chronic GVHD | ||||
| Overall | 14% (6–34) | 15% (5–43) | 32% (16–61) | 0.284 |
| Moderate + severe | 10% (4–30) | 10% (3–37) | 26% (12–56) | 0.238 |
| NRM@4y | 7% (2–26) | 0% NA | 21% (9–50) | 0.067 |
| CIR@4y | 21% (10–42) | 31% (16–60) | 11% (3–39) | 0.369 |
| PFS@4y | 72% (58–91) | 69% (51–93) | 68% (50–93) | 0.988 |
| OS@4 y | 76% (62–93) | 80% (64–100) | 68% (50–93) | 0.654 |
| GRFS@2 y | 59% (43–80) | 50% (32–78) | 42% (25–71) | 0.547 |
HAPLOD haploidentical donor, MSD matched sibling donor, URD unrelated donor, NRM nonrelapse mortality, OS overall survival, PFS progression free survival, CIR cumulative incidence of relapse, GRFS graft-relapse free survival